Exploring the role of targeted radiopharmaceutical treatment in NETs

Welcome to the Oncology Brothers podcast! In this episode, we dive into the evolving landscape of neuroendocrine tumors (NETs) with guests Dr. Heloisa Soares, a medical oncologist, and Prof. Ken Herrmann, a nuclear medicine specialist. Together, we explored the role of Peptide Receptor Radionuclide Therapy (PRRT), imaging breakthroughs, and treatment sequencing to optimize outcomes for NET patients. We cover essential topics such as: The role of Gallium-68 and Copper-64 DOTATATE PET imaging in diagnosis and planning Second-line standard use of PRRT and emerging data for first-line therapy Toxicities of PRRT—nausea, kidney toxicity, and bone marrow suppression Balancing sequencing strategies in well-differentiated and higher-grade tumors ⁠The critical role of multidisciplinary tumor boards in NET management Future directions including PRRT retreatment and ongoing clinical trials Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology! #NeuroendocrineTumors #NETs #PRRT #OncologyBrothers #CancerTreatment #NuclearMedicine